ArticlePloS one2023
Characteristics of medication-induced xerostomia and effect of treatment.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- EFFECT OF AN ORAL HEALTH PROMOTION PROGRAM ON GASTROPLASTY PATIENTS: A RANDOMIZED CLINICAL TRIAL.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2024Trial
- Xerogenic medications and clinical markers of salivary hypofunction.Clinical oral investigations · 2026Article
- The Role of Saliva in Swallowing: A Systematic Review.Dysphagia · 2026Review
- Impact of TCAs and Gabapentin on Saliva and BMI in Adults With Xerostomia.Journal of oral rehabilitation · 2026Article
- Dental Caries in Older Adults: A Narrative Review for Non-Dental Providers.International journal of environmental research and public health · 2026Review
- Validity and reliability of the total rating of eye, nasal, and dry-mouth (TREND) score.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Hyposalivation Treatment with Non-Crosslinked Hyaluronic Acid and Amino Acids Solution-A Clinical Pilot Study.Life (Basel, Switzerland) · 2026Article
- Comparable Effectiveness of Novel and Commercial Saliva Substitute Gels in Dental Patients Experiencing Xerostomia: A Randomized, Double-Blind Crossover Trial.Gels (Basel, Switzerland) · 2026Article
- Xerostomia as an oral-systemic indicator: Etiology, diagnostic strategies and multimodal management approaches.Bioinformation · 2026Article
- Impact of polypharmacy on oral health in the elderly: challenges and management.Frontiers in dental medicine · 2026Review
- Identifying subtypes of functional dentition in older adults: a population-based regression and latent class analysis.Clinical oral investigations · 2025Article
- Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma-A Literature Review.Dentistry journal · 2025Review
- Challenges and solutions in managing dental problems in children with autism.World journal of clinical pediatrics · 2025Article
- Examining the relationship between oral health indicators, obesity, and Xerostomia in older adults.BMC public health · 2025Article
- Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and β3-adrenoceptor agonists.Scientific reports · 2025Observational
- Photobiomodulation therapy for salivary gland hypofunction: a preliminary human study.Lasers in medical science · 2025Article
- Medication Purchases Are Associated With the Number of Dental Treatments.Clinical and experimental dental research · 2025Article
- Comparative Mucosal Wetting Capacity of Novel and Commercial Saliva Substitute Formulations: An in vitro Study.Clinical, cosmetic and investigational dentistry · 2025Article
- Clinical outcomes of NBF gel application in managing mucositis associated with xerostomia.Maxillofacial plastic and reconstructive surgery · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSide-effects of medications cause xerostomia. There have been cases where a medication has been discontinued owing to its severe side-effects. Therefore, the xerostomia must be treated to ensure that the primary disease is managed effectively. This study analyzed the actual status of patients with medication-induced xerostomia and investigates factors associated with its improvement.
methodsThis study assessed 490 patients diagnosed with medication-induced xerostomia who had an unstimulated salivary flow of ≤0.1 mL/min and received treatment for xerostomia at a xerostomia clinic. Patient age, sex, medical history, medications used, disease duration of xerostomia, and psychological disorders were recorded. The anticholinergic burden was assessed using the Anticholinergic Cognitive Burden scale. The unstimulated salivary flow was measured by the spitting method. According to their symptoms and diagnoses, the patients were introduced to oral lubricants, instructed on how to perform massage, and prescribed Japanese herbal medicines, and sialogogues. Factors associated with the subjective improvement of xerostomia and objective changes in the salivary flow rate were recorded at six months.
resultsXerostomia improved in 338 patients (75.3%). The improvement rate was significantly lower in patients with psychiatric disorders (63.6%) (P = 0.009). The improvement rate decreased as more anticholinergics were used (P = 0.018). However, xerostomia improved in approximately 60% of patients receiving three or more anticholinergics. The unstimulated salivary flow increased significantly more in patients who reported an improvement of xerostomia (0.033±0.053 mL/min) than in those who reported no improvement (0.013±0.02 mL/min) (P = 0.025).
conclusionXerostomia treatment improved oral dryness in 75.3% of patients receiving xerogenic medications in this study. If xerostomia due to side-effects of medications can be improved by treatment, it will greatly contribute to the quality of life of patients with xerogenic medications and may reduce the number of patients who discontinue medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.